Back to Events

In the Valley | Nov 18 | Eugene

Connect with your colleagues

Tuesday, November 18, 2025
5:00 PM - 8:00 PM (PST)

Knight Campus | University of Oregon

1505 Franklin Boulevard
Eugene, OR 97403
United States

In the Valley, part of Oregon Life Sciences’ regionally rotating “Bio On” series launched in 2007, brings together our vibrant life sciences community for an evening of connection, engagement, and education. Development experts, service partners, investors, students, and biotech enthusiasts gather to network and hear from local innovators shaping Oregon’s life science landscape.

This evening's program will feature a startup panel moderated by Rachel Jagoda Brunette, CEO of RAIN Catalysts and lead of the Cascades West Innovation Hub, highlighting emerging companies launched from the University of Oregon ecosystem. Panelists include Craig Stolarczyk, CEO and Cofounder of SynPlexityChris Adamek, President of VivoTex, and Stephen Laffoon, CEO of Penderia Technologies, who will share their journeys in translating university research into commercial ventures, lessons learned along the way, and perspectives on building and growing a biotech company in Oregon.

Whether you’re a biotech veteran, new to the field, or simply curious, all are welcome to join us for this evening of discovery and community.

Agenda

November 18
5:00 PM - 5:30 PM Check-in | Welcome Doors open
5:30 PM - 6:15 PM Program
6:15 PM - 8:00 PM Networking

Rachel Jagoda Brunette is the CEO of the Regional Accelerator and Innovation Network (RAIN) and leads the Cascades West Innovation Hub, which supports innovation-based entrepreneurs in rural Oregon through technical assistance, mentorship, and ecosystem building.
Before joining RAIN, Rachel served as a Philanthropic Director at Foundation Source, advising private and corporate foundations on strategy, program design, and impact measurement. From 2014–21, she led The Lemelson Foundation’s Regional Ecosystems initiative, advancing entrepreneurship and innovation programs across Oregon and nationally. Earlier in her career, Rachel worked in federal science, technology, and education policy as professional staff on the U.S. House Committee on Science and Technology, contributing to major legislation including the America COMPETES Act. She has also supported technology and education policy in Oregon at the local level. Rachel serves on the boards of VertueLab, the Oregon Economic Development Association, and the TiE Oregon Foundation. She holds degrees from Georgetown and George Washington University.

Chris Adamek is the President of VivoTex and focuses on the development and implementation of the business strategy, leading commercialization efforts and collaborating with investors.  Chris was previously the COO for 4G Clinical and held positions as the COO for Columbia Sportswear (Columbia Brand) & Vice President of North Highland.

Stephen Laffoon is Chief Executive Officer of Penderia Technologies, a Phil and Penny Knight Campus based medical device startup with a vision to commercialize sensor technology for orthopedic surgical procedures. Stephen's career has spanned 19 years, with 14 FDA clearances, 20+ patents, 2 acquisitions, and hundreds of thousands of devices implanted. Stephen completed his BSME from Georgia Tech in 2006 and began his career in medical device manufacturing technology for CR Bard. He then used his manufacturing knowledge to move into product development and connect with technologies from academia. Among them, Stephen was co-founder and Director of Engineering for Vertera Spine, who collaborated with the Guldberg and Gall labs to commercialize the first clinical application of porous PEEK in spinal fusion procedures. Founded in 2013, Vertera was acquired by NuVasive (now Globus) in 2017. Stephen oversaw the technical aspects of acquisition integration and remained with NuVasive post-integration in a management role until he joined Penderia in the spring of 2023. 

Craig Stolarczyk is the co-founder and CEO of SynPlexity, a company spun out of the Knight Campus at the University of Oregon. His path has taken him from industrial chemistry through next-gen sequencing and proteomics, and now into synthetic biology, where his team is building a platform to scale multiplexed gene synthesis. He thrives at the intersection of deep science and business execution, taking ideas from lab benches to markets. Along the way he has raised venture capital, secured IP licenses, and led product and business development efforts.

Tickets – Oregon Life Sciences Members
$35: Early Bird rate - expired Nov. 7
$55: Standard Online rate
*All employees of Oregon Life Sciences Member companies are eligible. You must be logged in to access member pricing. 

Tickets –  Non Members
$90: Standard online rate

Oregon Life Sciences does not offer refunds for events, however we can transfer tickets upon request.

Please note:  Oregon Life Sciences takes photos and videos at our events which are used for marketing purposes. By purchasing a ticket to this event, you agree and consent to our use of your image and voice as recorded during the event.